What Are the Current Belviq Recalls or Warnings?
When Belviq was released to the general public, there were already warning signs of its link to cancerous tumors. Early tests conducted on rats resulted in instances of tumor growth and cancer-related deaths. Belviq’s manufacturer assured the FDA that these issues were resolved and claimed that the results were still safely within margins. The FDA decided to approve Belviq and it’s extended release formula, Belviq XR.
Several years after the results of the clinical trials were released, the FDA recalled Belviq and Belviq XR from the market when it was determined that the potential cancer risks were too high to ignore.
The FDA does not recommend any special screening for individuals who have taken Belviq at this time, but they do suggest speaking with a healthcare professional if you have any questions or concerns.
What Kinds of Cancer is Belviq Purported to Have Caused so Far?
15 types of cancer have been reported to the FDA’s FAERS.
These 15 varieties of cancer were submitted in adverse reports from eight patients.
If you would like to learn more about possible cancers linked to the use of Belviq, contact a Belviq attorney for a free case evaluation.
Belviq Drug Labeling and Cancer
The product label on Belviq does not feature any warnings about the heightened risk of cancer. It does present some data from studies involving rats and the cancer they allegedly had during trials, and other warnings about potential white and red blood cell count decreases. The label also warns of a potential elevated level of the protein prolactin.
Speak With a Belviq Lawsuit Attorney
If you believe you are entitled to compensation due to a cancer diagnosis after taking Belviq, contact our Belviq Lawsuit Lawyers for more information.